Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04553068 · ClinicalTrials.gov registry record · Phase 3
Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection
A Phase 3 study, sponsored by Evofem.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,892
- Enrollment target
NCT04553068: Completed Phase 3 study, sponsored by Evofem.
NCT04553068 is a Phase 3 study that has completed, run by Evofem. The registered enrollment target is 1,892 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (145% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04553068, a Phase 3 study, has completed, sponsored by Evofem.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,892 participants
- Enrollment target
Study Summary
This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection
Primary Outcome
Percentage of subjects who are defined study successes among the intervention groups with success defined as subjects completing the trial to Visit 5 without any CT or GC infection and no usage of prohibited antibiotics during the study.
Interventions
- DRUG Placebo
- DRUG EVO100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,892 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2022-07-28 |
| Phase | Phase 3 |
What the finished NCT04553068 record still lists
NCT04553068 is an interventional study that assigns participants to a tested intervention. Its 1,892 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (145% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04553068 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04553068 about?
NCT04553068 is a clinical study titled "Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection". This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection
What is the current status of trial NCT04553068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,892 participants. The study started on 2020-10-15. Estimated completion is 2022-07-28.
What interventions are being tested in trial NCT04553068?
The interventions under investigation include: Placebo (DRUG), EVO100 (DRUG).
Who is sponsoring clinical trial NCT04553068?
This trial is sponsored by Evofem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04553068's enrollment target sits among peer trials
1,892 113th of 2000 higher than 1,888 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07308717 · 1,896 participants · Phase 4
Gabapentin And Breast Surgery Decision Architecture Randomization Trial (GABS-DART) Protocol
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
- NCT06929806 · 1,900 participants · Phase 3
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI